Page 24«..1020..23242526..3040..»

Category Archives: Global News Feed

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Posted: February 5, 2025 at 2:42 am

TEL AVIV, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of a patent application in Mexico for the innovative combination of 3,4-Methylenedioxymethamphetamine (MDMA) with N-Acylethanolamines.

Continued here:
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Posted in Global News Feed | Comments Off on SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness

Posted: February 5, 2025 at 2:42 am

Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss in adults with diabetes, affecting more than 29 million adults worldwide.1-3 Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections.4-6 Susvimo is now available to US retina specialists and their patients with DME.

More:
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness

Posted in Global News Feed | Comments Off on FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

Posted: February 5, 2025 at 2:42 am

ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch.

See the original post here:
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

Posted in Global News Feed | Comments Off on Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Posted: February 5, 2025 at 2:42 am

Dr. Jennifer Kissner, SVP Clinical Development, discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trial

Read this article:
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Posted in Global News Feed | Comments Off on Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

Posted: February 5, 2025 at 2:42 am

Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product launch later this year, which is expected to generate near-term revenues while the Company advances its clinical trials.

Follow this link:
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

Posted in Global News Feed | Comments Off on Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Posted: February 5, 2025 at 2:42 am

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2025, it awarded an inducement grant to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.

See the article here:
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Posted in Global News Feed | Comments Off on Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Posted: February 5, 2025 at 2:42 am

REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that its management will present at the Oppenheimer Healthcare Life Sciences Conference, taking place February 11-12, 2025.

Continue reading here:
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Posted in Global News Feed | Comments Off on Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®

Posted: February 5, 2025 at 2:42 am

Saint Herblain (France), February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for the world’s first and only chikungunya vaccine, IXCHIQ®. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older. The vaccine is manufactured at Valneva’s leading vaccine production site in Livingston, Scotland.

See the article here:
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®

Posted in Global News Feed | Comments Off on Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®

Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea

Posted: February 5, 2025 at 2:42 am

Allschwil, Switzerland, February 05, 2025

See the article here:
Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea

Posted in Global News Feed | Comments Off on Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea

Novo Nordisk’s sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Posted: February 5, 2025 at 2:42 am

Bagsværd, 5 February 2025 - Financial report for the period 1 January 2024 to 31 December 2024

Read the original here:
Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Posted in Global News Feed | Comments Off on Novo Nordisk’s sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Page 24«..1020..23242526..3040..»